Literature DB >> 27365784

Role of prophylactic surfactant in preterm infants.

Daljit Singh1, K S Rana2, Sheila Mathai3.   

Abstract

BACKGROUND: Respiratory distress syndrome (RDS) in preterm neonates is caused by a deficiency or dysfunction of pulmonary surfactant. The physiological function of surfactant includes the ability to lower surface tension, as well as the ability to rapidly adsorb and spread. A wide variety of surfactant products have been formulated and studied in clinical trials. The present study was designed to find out whether prophylactic administration of surfactant leads to a significant decrease in the risk of neonatal mortality and neonatal morbidity.
METHODS: This was an experimental study in which a total of 125 preterm newborns less than 34 weeks gestation were studied. One hundred preterm newborns (controls) less than 34 weeks gestation were managed in the conventional manner as per the existing protocols in the neonatal intensive care unit. Twenty-five consecutively delivered preterm newborns less than 34 weeks gestation were administered surfactant. Data regarding clinical outcomes including mortality and morbidity profile was collected and analysed.
RESULTS: The mean duration of ventilation in the ventilated babies in the control group and the surfactant group was 129.8 ± 43 hours and 85.7 ± 46 hours, respectively; the difference being statistically significant. In the surfactant group, four babies (16%) died and in the control group, 27 babies (27%) died. The difference was not statistically significant. The number of babies developing retinopathy of prematurity and needing laser treatment for retinopathy of prematurity was greater in the surfactant group.
CONCLUSION: Prophylactic administration of surfactant in preterm newborns of gestational age < 34 weeks is associated with a significant decrease in mean duration of ventilation and an increase in the incidence of retinopathy of prematurity.

Entities:  

Keywords:  neonates; preterm; surfactant

Year:  2011        PMID: 27365784      PMCID: PMC4920685          DOI: 10.1016/S0377-1237(11)60012-9

Source DB:  PubMed          Journal:  Med J Armed Forces India        ISSN: 0377-1237


  27 in total

1.  Single dose surfactant rescue therapy in neonatal respiratory distress syndrome.

Authors:  K P Sanghvi; R H Merchant
Journal:  Indian Pediatr       Date:  1998-06       Impact factor: 1.411

2.  Improved outcome at 28 days of age for very low birth weight infants treated with a single dose of a synthetic surfactant.

Authors:  C Bose; A Corbet; G Bose; J Garcia-Prats; L Lombardy; D Wold; D Donlon; W Long
Journal:  J Pediatr       Date:  1990-12       Impact factor: 4.406

Review 3.  History of surfactant up to 1980.

Authors:  Michael Obladen
Journal:  Biol Neonate       Date:  2005-06-01

4.  Controlled trial of a single dose of synthetic surfactant at birth in premature infants weighing 500 to 699 grams. The American Exosurf Neonatal Study Group I.

Authors:  D Stevenson; F Walther; W Long; M Sell; T Pauly; A Gong; D Easa; A Pramanik; M LeBlanc; E Anday
Journal:  J Pediatr       Date:  1992-02       Impact factor: 4.406

5.  Decreased mortality rate among small premature infants treated at birth with a single dose of synthetic surfactant: a multicenter controlled trial. American Exosurf Pediatric Study Group 1.

Authors:  A Corbet; R Bucciarelli; S Goldman; M Mammel; D Wold; W Long
Journal:  J Pediatr       Date:  1991-02       Impact factor: 4.406

6.  Lung surfactant and the pathogenesis of neonatal bronchiolar lesions induced by artificial ventilation.

Authors:  R Nilsson; G Grossmann; B Robertson
Journal:  Pediatr Res       Date:  1978-04       Impact factor: 3.756

7.  Ten centre trial of artificial surfactant (artificial lung expanding compound) in very premature babies. Ten Centre Study Group.

Authors: 
Journal:  Br Med J (Clin Res Ed)       Date:  1987-04-18

8.  Recent clinical trials of surfactant treatment for neonates.

Authors:  Henry L Halliday
Journal:  Biol Neonate       Date:  2006-06-01

9.  Prevention of neonatal respiratory distress syndrome by tracheal instillation of surfactant: a randomized clinical trial.

Authors:  G Enhorning; A Shennan; F Possmayer; M Dunn; C P Chen; J Milligan
Journal:  Pediatrics       Date:  1985-08       Impact factor: 7.124

10.  Double-blind clinical trial of calf lung surfactant extract for the prevention of hyaline membrane disease in extremely premature infants.

Authors:  M S Kwong; E A Egan; R H Notter; D L Shapiro
Journal:  Pediatrics       Date:  1985-10       Impact factor: 7.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.